Radiofrequency (RF) for MGD

Radiofrequency treatment uses electromagnetic energy to generate heat within tissue. Unlike a warm compress, which transfers heat from a hot object through the skin, RF energy produces heating through the interaction of electrical energy with tissue.

RF has been used for many years in other areas of medicine and aesthetic dermatology. Its application to meibomian gland dysfunction is much newer.

The proposed advantage is that RF may produce controlled heating within periocular tissues, potentially reaching temperatures capable of changing the physical properties of abnormal meibum.

The word radiofrequency can sound alarming, but RF treatment does not use ionizing radiation such as X-rays. It uses electromagnetic energy at frequencies that can generate controlled tissue heating. So the relevant biological effect here is primarily thermal energy.

That does not mean RF is automatically harmless. Any technology capable of significantly heating tissue needs appropriate controls. But it is not the same kind of radiation used in medical imaging or radiotherapy.

The simplest proposed mechanism is similar to the principle behind other heat-based MGD treatments:

RF energy→controlled tissue heating→increased meibum fluidity→easier gland secretion and outflow

If thick, poorly flowing meibum is an important part of the patient’s MGD, this is a biologically plausible target.

But as with warm compresses, RF does not literally need to “melt a plug.” The more accurate idea is that heating can alter the physical properties of meibum and make it easier to move.

Warm Compresses for MGD: the simplest form of heat

Primarily in how the heat is generated and delivered. A warm compress heats the outer eyelid surface, and heat then has to conduct through the eyelid toward the meibomian glands. RF energy can generate heating within tissue rather than relying entirely on surface-to-depth heat transfer.

In theory, this could provide deeper, more controlled or more sustained heating.

But there is an important rule we should keep throughout this guide: a theoretically better way of delivering heat is not automatically a clinically better treatment. That has to be demonstrated in comparative trials.

No. Both treatments involve heat, but they work differently. Thermal pulsation systems such as LipiFlow combine controlled eyelid heating with mechanical pulsation and pressure. RF primarily uses electromagnetic energy to heat tissue. Some RF protocols are then followed by manual meibomian gland expression, so RF itself does not necessarily provide the same mechanical evacuation component as thermal pulsation.

This distinction matters when comparing studies. If a study uses RF plus gland expression, we cannot automatically attribute the entire result to RF.

Thermal Pulsation (LipiFlow) for MGD

No. IPL uses high-intensity pulses of broad-spectrum light. Its proposed effects include:

• •vascular photothermolysis
• •modulation of inflammation
• •thermal effects
• •and possibly effects on Demodex and the lid-margin environment

RF does not rely on light or hemoglobin absorption. Its most obvious biological effect in MGD treatment is controlled tissue heating. So although both treatments can produce heat, they are fundamentally different technologies.

IPL for Dry Eye and MGD

This is often mentioned in descriptions of RF treatment, but we should be careful. Heating tissue can potentially influence multiple biological processes, and improvements in gland function may themselves change the inflammatory environment of the ocular surface.

However, the clinical evidence for RF in MGD is still developing. At this stage, it is much safer to say that RF may have biological effects beyond simply changing meibum fluidity than to claim that RF is an established anti-inflammatory treatment for dry eye. The mechanism needs considerably more study.

This is another claim that comes largely from RF’s dermatological and aesthetic applications. Controlled RF heating can induce collagen remodeling in skin, which is one reason RF is widely used for cosmetic skin tightening.

But “RF can stimulate collagen in skin” does not automatically mean “collagen stimulation treats MGD.” Those are two separate claims. If an RF treatment improves MGD, we need evidence connecting the biological effect to meibomian gland function, tear-film stability or symptoms. The fact that the same device may also affect skin collagen does not establish that collagen remodeling is responsible for the dry-eye benefit.

The evidence base is growing, but it is still relatively small. Earlier studies often used RF together with other treatments, making it difficult to determine how much benefit came from RF itself.

For example, a 2023 prospective study treated patients with IPL + RF + meibomian gland expression. After four treatments, meibum quality and symptoms improved substantially. But because all three treatments were used together, the study could not tell us how much of that improvement was specifically caused by RF. The authors themselves stated that a randomized trial comparing IPL + RF + expression with IPL + expression was needed to determine RF’s contribution.

That is a very important limitation.

Yes, and this is an important recent development. A randomized controlled trial specifically investigating radiofrequency treatment for meibomian gland dysfunction was published in The Ocular Surface in 2026. This is encouraging because it begins to move the RF evidence beyond uncontrolled studies and combination protocols.

But one randomized trial does not suddenly give RF the same evidence base as treatments that have been evaluated across numerous independent trials and systematic reviews.

So as of 2026, I would describe RF as promising, increasingly studied, but still an emerging MGD treatment.

This combination is becoming increasingly common, and there is some clinical evidence suggesting that patients can improve after combined treatment.

A 2026 comparative study evaluated three groups: RF alone, IPL alone, and RF + IPL. All three groups improved in symptoms, tear break-up time and meibomian gland measures, with the combined group showing larger improvements across several outcomes.

That is interesting. But it does not automatically establish that RF + IPL is the best MGD treatment. Study design, patient selection, sample size, treatment protocols and independent replication all matter.

And combination therapy introduces another problem: the more treatments we perform simultaneously, the harder it becomes to know which component was actually necessary.

Imagine someone receives IPL, then RF, then gland expression during the same treatment session. Three months later their glands are functioning much better.

What worked? IPL? RF? Expression? All three? Would IPL + expression have produced almost the same result? Would RF + expression have been enough? Could expression alone have produced part of the improvement?

Unless the study contains appropriate comparison groups, we cannot answer those questions. This is why a dramatic before-and-after result does not necessarily tell us which treatment produced it.

Based on its proposed mechanism, RF makes the most intuitive sense when there is:

• •viable meibomian gland tissue
• •thick or poorly flowing meibum
• •impaired gland outflow

In that situation, controlled tissue heating has a clear target. But this is still partly a mechanistic argument. We need better evidence identifying which patient characteristics actually predict a good clinical response to RF. That is different from simply showing that the average patient in a study improved.

RF cannot heat a gland that is no longer present. Like other heat-based treatments, its potential is limited by how much viable glandular tissue remains.

That does not necessarily mean someone with substantial dropout cannot benefit. The remaining glands may still function poorly and potentially respond to treatment. But expectations should be realistic: improving remaining gland function is different from replacing lost glands.

At present, we do not have convincing evidence that RF regenerates truly lost meibomian gland tissue. This is particularly important because RF is sometimes marketed using words such as:

• •regeneration
• •rejuvenation
• •restoration

Those terms can mean many different things. Improved gland secretion is not the same as anatomical gland regeneration. A change in meibography appearance is not automatically proof that previously lost gland tissue has grown back. Unless robust longitudinal imaging and biological evidence demonstrate true regeneration, that claim should be treated cautiously.

Not necessarily. This is exactly the same logical problem we encountered earlier. Suppose RF heats tissue deeper than a warm compress. That tells us something about energy delivery. It does not automatically tell us that patients will:

• •feel better
• •produce better meibum
• •have more stable tears

than they would after another treatment. Clinical benefit has to be measured directly.

The goal is not to heat the deepest. The goal is to improve the relevant biological problem safely.

This depends on the device and protocol. RF systems can monitor or target specific surface temperatures, while actual temperatures deeper in tissue may differ. Different devices also use different:

• •frequencies
• •power settings
• •electrode configurations
• •and treatment durations

That means “I had RF” does not necessarily describe one standardized treatment. Just as with IPL, device and protocol matter.

No. RF is not a treatment where more power equals more benefit. Higher energy produces more heating, but tissue has a safe thermal range, and excessive heating can cause injury. The goal is controlled therapeutic heating, not maximal heating.

Settings therefore need to follow the specific device protocol and take into account the treatment area and individual patient.

Any device capable of producing substantial tissue heating has the potential to cause thermal injury if used incorrectly. Modern medical RF systems are designed to control temperature and reduce this risk.

Published MGD studies so far have generally reported good tolerability and no major safety signals, including recent comparative research in which no serious adverse events were reported. But the current MGD safety database is still much smaller than that for older treatments.

So “no major safety signal so far” is not the same as “we know every uncommon long-term risk.”

This is a question people sometimes ask because RF devices are also used in aesthetic medicine, including technologies intended to affect subcutaneous tissue. But not all RF devices, energies or treatment depths are the same. We should therefore not take an adverse effect associated with one aesthetic RF technology and automatically assume it applies to every periocular MGD protocol.

At the same time, because the eyelid and periocular area contain delicate structures, device-specific safety data matter. If RF is being used near the eyes, useful questions include:

• •Which device is being used?
• •Is it specifically intended or studied for periocular/MGD treatment?
• •What temperatures and settings are used?
• •What tissues are being targeted?

These are more meaningful questions than simply asking whether “RF” as a category is safe.

There is no universally established RF protocol for MGD. Studies have used treatment series rather than one identical schedule. Some combination protocols, for example, have used four sessions approximately two weeks apart.

But that does not establish four sessions every two weeks as the correct protocol for every RF device or every patient. The technology is still too heterogeneous and the evidence too young for that.

We do not currently have strong evidence supporting a universal maintenance schedule. So recommendations such as “repeat RF every six months forever” should not be treated as an established scientific rule.

Return to the target. If the original problem was thick, poorly expressible meibum and gland function remains good after treatment, what exactly are we treating by repeating RF? If dysfunction returns, retreatment may be considered. But treatment should ideally follow recurrent dysfunction, not simply the calendar.

Treating Dry Eye: start with the target

We don’t know, and at this point I would be particularly skeptical of confident claims that one is clearly superior.

IPL has a larger MGD evidence base and proposed biological effects beyond heating, including vascular and inflammatory pathways. RF has a particularly intuitive thermal mechanism and increasingly interesting clinical data. They may also be useful for somewhat different patient phenotypes. Direct, high-quality comparative evidence remains limited.

So the useful question is not “Which machine is stronger?” It is “Which biological problem are we trying to treat?”

Again, we do not currently have enough high-quality head-to-head evidence to answer that confidently. Both involve heat, but LipiFlow combines controlled heating with mechanical pulsation, while RF creates controlled tissue heating and may be combined separately with expression. They are not identical treatments. Until strong comparative trials exist, claims of superiority should be treated cautiously.

This is where the evidence level matters. TFOS DEWS III recognizes that MGD management now includes a broad range of device-based and emerging technologies in addition to established approaches such as warm compresses and IPL. RF is increasingly part of that landscape.

But it would be misleading to present the evidence for RF as equally mature. The field is developing quickly. That is exciting. It also means conclusions should remain proportionate to the evidence.

Ask exactly the same questions we have used throughout this section:

• •What abnormality are we trying to treat?
• •Why is RF appropriate for that abnormality?
• •Which RF device is being used?
• •What clinical evidence exists for that particular approach?
• •Is RF being used alone or together with IPL/expression?
• •What outcome should improve?
• •What are the risks?
• •How will we know whether it worked?

And one particularly useful question: what evidence shows that RF adds something beyond the other treatments I am receiving? That question becomes very important when several procedures are bundled together.

How to Choose a Dry Eye Treatment